PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Geelong, VIC, Australia.\', \'Commonwealth Scientific and Industrial Research Organisation, Data61, Docklands, VIC, Australia.\', \'Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital and The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.\', \'Research & Development Centre, Inovio Pharmaceuticals, San Diego, CA, United States.\', \'Department of Health Sciences, University of York, York, United Kingdom.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3389/fimmu.2021.694857
?:doi
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 34248993
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
?:title
  • Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34248993>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34248993>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all